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ABSTRACT  
BACKGROUND 
Over the past years, PET imaging studies have investigated striatal molecular changes 
in premanifest and manifest Huntington’s disease gene expansion carriers (HDGECs), 
but they have yielded inconsistent results. 
OBJECTIVE 
To systematically examine the evidence of striatal molecular alterations in manifest 
and premanifest HDGECs as measured by PET imaging studies. 
METHODS 
MEDLINE, ISI Web of Science, Cochrane Library and Scopus databases were 
searched for articles published until 7th June 2017 that included PET studies in 
manifest and premanifest HDGECs. Meta-analyses were conducted with random 
effect models and heterogeneity was addressed with I2 index, controlling for 
publication bias and quality of study. The primary outcome was the standardized 
mean difference (SMD) of PET uptakes in the whole striatum, caudate, and putamen 
in manifest and premanifest HDGECs compared with healthy controls (HCs).  
RESULTS 
Twenty-four out of 63 PET studies in premanifest (n=158) and manifest (n=191) 
HDGECs and HCs (n=333) were included in the meta-analysis. Premanifest and 
manifest HDGECs showed significant decreases in dopamine D2 receptors in caudate 
(SMD=−1.233, 95% CI=−1.753 to −0.713, P<0.0001; SMD=−5.792, 95% CI=−7.695 
to −3.890, P<0.0001) and putamen (SMD=−1.479, 95% CI=−1.965 to −0.992, 
P<0.0001; SMD=−5.053, 95% CI=−6.558 to −3.549, P<0.0001), in glucose 
metabolism in caudate (SMD=−0.758, 95% CI=−1.139 to −0.376, P<0.0001; 
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SMD=−3.738, 95% CI=−4.880 to −2.597, P<0.0001) and putamen (SMD=−2.462, 
95% CI=−4.208 to −0.717, P=0.006; SMD=−1.650, 95% CI=−2.842 to −0.458, 
P<0.001) and in striatal PDE10A binding (SMD=−1.663, 95% CI=−2.603 to −0.723, 
P=0.001; SMD=−2.445, 95% CI=−3.371 to −1.519, P<0.001).  
CONCLUSIONS  
PET imaging has the potential to detect striatal molecular changes even at the early 
premanifest stage of HD, which are relevant to the neuropathological mechanisms 
underlying the development of the disease.  
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INTRODUCTION  
Huntington’s disease (HD) is an inherited, neurodegenerative disorder caused by 
CAG repeat expansion in huntingtin gene (HTT). HD is clinically characterized by 
progressive motor dysfunction, cognitive decline, and psychiatric disturbances and 
will eventually lead to death, typically 15-20 years following symptomatic onset.1 The 
onset of symptoms is inversely associated with the size of the CAG repeat expansion 
and most commonly occurs at the age of mid-40s.1 However, subclinical changes and 
pathological processes are thought to precede the initiation of symptoms by several 
years.2 The availability of genetic testing and the full penetrance of HTT mutation in 
people with more than 40 CAG expansions3 provide a unique window of opportunity 
to examine the pattern of signs, symptoms, and neurobiological changes as they 
emerge, and study the clinical course of HD before the development of overt 
symptoms. There is an urgent need to identify biomarkers that are able to monitor 
disease progression and assess the development and efficacy of novel disease 
modifying drugs. 
 
HD pathology is characterised by the formation of intranuclear inclusions of mutated 
huntingtin preferentially in the striatal GABAergic medium spiny neurons (MSNs). 
These aggregates hamper intracellular processes, such as gene transcription, protein 
trafficking, neurotransmitters release and mitochondrial function, leading to the loss 
of striatal MSNs.1 Thus striatal molecular changes have great relevance to HD 
pathology and may provide a valuable tool to monitor disease progression and assess 
the efficacy of novel disease-modifying drugs. 
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Positron emission tomography (PET) is a molecular imaging technique for the 
quantitative and non-invasive imaging of biological functions. The distribution and 
kinetic profiles of compounds targeting specific biological molecules in tissue reflect 
specific biological functions in the living body. There are no good alternatives to PET 
in directly evaluating human neurochemistry. Previous PET imaging studies 
investigating striatal molecular changes in premanifest and manifest HDGECs have 
yielded inconsistent results mainly due to the heterogeneous and small sample size 
and different inclusion criteria used in these studies.4  
 
In this systemic review and meta-analysis, we aim to systematically examine the 
evidence of in vivo striatal molecular changes in premanifest and manifest HD gene 
expansion carriers (HDGECs) as measured by PET imaging studies and to 
quantitatively estimate their magnitude. We hypothesize that striatal molecular 
changes are consistently impaired in manifest HDGECs as compared to controls as 
key neurobiological marker of the disease. These molecular changes may be already 
evident at the premanifest stage although the magnitude of these alterations may be 
more severe in the manifest as compared to premanifest HDGECs.  
 
METHODS 
The study was designed according to the PRISMA (Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses) guidelines and recommendations from the 
Cochrane Collaboration and Meta-analysis Of Observational Studies in Epidemiology 
(MOOSE).5 
 
Search Strategy 
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MEDLINE, ISI Web of Science, Cochrane Library and Scopus databases electronic 
databases were searched for articles published from 1980 until 7th June 2017. Only 
full manuscripts were included in this meta-analysis. Gray literature (ie, abstract or 
conference proceedings) was not considered as a priority asset of our systematic 
review. Studies were identified, combining the following major Medical Subject 
Headings: “Huntington’s disease” and “PET” combined with text and key words for 
MEDLINE as example: ((“Huntington Disease” [MeSH Terms] OR “Huntington's” 
OR “Huntington's chorea” OR “chorea” [MeSH Terms] OR “hereditary chorea” OR 
“progressive chorea” OR “late onset Huntington disease” OR “juvenile Huntington 
disease” OR “akinetic rigid variant Huntington disease”) AND (“Positron-Emission 
Tomography” [MeSH Terms] OR “positron emission tomography” OR “PET”)). 
Additional eligible studies were identified through manual screening of the reference 
lists of studies included in our analysis. Corresponding authors were contacted by e-
mail requesting meta-analytical details that were not included in the original 
manuscripts. 
 
Selection Criteria 
All selected titles and abstracts were independently reviewed by two authors (FN, GP) 
and then discussed with a third independent author (MP). Selected studies were 
eligible if they met the following criteria: (a) cross-sectional, case control or 
longitudinal studies including manifest or premanifest HDGECs compared with a 
healthy control (HC) group, (b) published in peer-reviewed international journals in 
English language, (c) confirmed HDGECs diagnosis on the basis of clinical 
symptoms and/or positive genetic test for CAG repeat, (d) classification as 
premanifest HDGECs as established by positive genetic test for CAG repeat and 
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absence of motor signs based on the standardized total motor score (TMS) subscale 
(TMS = 0) of the Unified Huntington Disease Rating Scale (UHDRS) with a 
diagnostic confidence level of 0,6 and (e) PET measures in caudate, putamen or whole 
striatum reported as mean ± standard deviation (SD) in premanifest and manifest 
HDGECs and healthy control (HC) subjects. We excluded the following studies: (a) 
PET studies reporting changes in PET measures in subjects at risk of HD but not 
tested for CAG repeat (n=9)7-15; (b) studies using only Statistical Parametric Mapping 
(SPM) analyses (n=12)16-27; (c) studies including overlapping samples.  In cases of 2 
or more studies from the same centre, we checked for overlapping samples by 
contacting the authors to verify that there was not a significant overlap in the samples. 
Striatal PET radioligands of interest included: [11C]Raclopride (dopamine D2 
receptors), [11C]SCH23390 (dopamine D1 receptors), [
11C]PK11195 (microglial 
activation), [18F]FDG (glucose metabolism), [11C]IMA107 [phosphodiesterase 10A 
(PDE10A)], [18F]JNJ42259152 (PDE10A), [18F]MNI-659 (PDE10A), [11C]FMZ 
(GABA benzodiazepine receptor), [18F]CPFPX [adenosine A1 (A1A) receptor], [
11C]β-
CIT [dopamine transporter (DAT)],  [11C]DTBZ [vesicular monoamine transporter 
type-2 (VMAT2)] and [18F]MK9470 [cannabinoid type 1 (CB1) receptor].  
 
Risk of bias in included studies 
The quality of the included studies was assessed by Newcastle-Ottawa Scale (NOS).28 
NOS is characterized by eight items including selection, comparability, and exposure 
(case-control studies) or outcome (cohort studies). The scale ranged from zero to six 
stars, the highest degree representing the greatest methodological quality. 
Disagreement was resolved by consensus and by opinion of a third reviewer (MP). 
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The presence of publication bias was explored by performing the test for asymmetry 
of the funnel plot by Egger.29 
 
Data extraction  
Two reviewers (FN, GP) independently completed the data extraction. The recorded 
variables for each article included in the meta-analysis were study year, author first 
name, disease stage (premanifest, manifest), gender, mean age of participants, number 
of participants, type of radiotracer used, disease duration (years), CAG repeat, 5-year 
probability to symptom onset according to the Langbehn formula,3 90% probability to 
symptom onset according to revised survival analysis formula for determining time to 
symptom onset.3  
 
Statistical Analysis 
Data were analysed using Comprehensive Meta-Analysis software, version 2 (Biostat, 
Englewood, N.J.). PET uptake in manifest and premanifest HDGECs compared with 
HCs was estimated through the standardized mean difference (SMD). The mean 
difference in the primary outcome measures (PET uptake) between patients 
(premanifest and manifest HDGECs) and HC group was standardized by calculating 
the difference between the two mean changes (difference of patients and HCs score) 
divided by the pooled SD of the difference scores. A negative change of the 
standardized mean difference (SMD) indicates a larger reduction in our primary 
outcome measures in the patients (premanifest and manifest HDGECs) as compared 
to HCs. Independent meta-analyses across each type of radiotracer were carried out. 
The results were pooled using the inverse variance method. Heterogeneity was 
assessed using I2 statistic that accounts of between-study (or inter-study) variability as 
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opposed to within-study (or intra-study) variability. Because of latent clinical 
heterogeneity, random effect models were used to synthesize data instead of fixed 
effect model, independently from statistical evidence of heterogeneity.30 
Heterogeneity was considered substantial if I2 value was greater than 50%.31 For 
completeness and clarity, we additionally calculated the percentage of change in the 
primary outcome measures between the HDGECs and HCs groups. All reported test 
results were two-tailed and statistical significance was set to a P<0.05.  
 
Sensitivity analyses 
To investigate the influence of individual studies on the meta-analytical results, we 
undertook one study-removed analysis by omitting one study in each meta-analysis 
and recalculating the pooled estimates on remaining studies.32 Meta-regression 
analysis to explore the influence of potential effect modifiers on striatal changes was 
not performed due to the small number of PET studies per each target (less than 10 
studies).33  
 
RESULTS 
Meta-analytical database 
The combined search strategies yielded a total of 702 references identified, of which 
63 were retrieved for detailed full-text evaluation and 24 were finally included in the 
meta-analysis (Figure 1).34-59 PET studies included in the systematic review and 
quantitative meta-analysis investigated striatal changes in dopamine D1
39,41,44 and D2 
receptors,39-42,44,46,47,51 glucose metabolism,34-37,40,44,45,49,50,54 microglial activation,46,59 
A1A receptor,
52 GABA benzodiazepine receptor,38 and presynaptic molecular changes 
(DAT and VMAT2)42,43 in manifest and premanifest HDGECs compared with HCs. 
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PET studies investigating the expression of PDE10A in premanifest and manifest 
HDGECs53,55,56 and  CB1 receptor density in manifest HDGECs
48 reported PET 
molecular changes in the whole striatum and were not included in the pooled analysis. 
Four PET studies have reported significant increases in striatal microglial activation 
in manifest HDGECs46,58-60 but due to overlapping cohort of subjects we have 
included only one study in the meta-analysis.46 Characteristics of the studies included 
are summarised in Table 1 and 2. The study populations in this meta-analysis 
included 333 HCs (mean age=46.9 years; 58.9 % male), 158 premanifest HDGECs 
(mean age =39 years; 40.6% male; mean CAGr=43.1) and 191 manifest HDGECs 
(mean age =47.7years; 54.2% male; mean CAGr =43.5). Manifest HDGECs had 
mean disease duration of 4.29 years (range 2.2 to 7.25) and premanifest HDGECs 
were on average 19.2 years (range 10.3 to 25) before the predicted symptomatic onset 
(90% probability). The quality of included studies was moderate or good, varying 
from three to six NOS stars (Table S1).  
 
Premanifest HDGECs 
Premanifest HDGECs showed significant decreases in dopamine D2 receptors in 
caudate (SMD=−1.233, 95% CI=−1.753 to −0.713, P<0.0001; I2=25.7%) and 
putamen (SMD=−1.479, 95% CI=−1.965 to −0.992, P<0.0001; I2=10.1%; Figure 2), 
in glucose metabolism in caudate (SMD=−0.758, 95% CI=−1.139 to −0.376, 
P<0.0001; I2=0.0%) and putamen (SMD=−2.462, 95% CI=−4.208 to −0.717, 
P=0.006; I2=88.6%; Figure 2) and in striatal PDE10A binding (SMD=−1.663, 95% 
CI=−2.603 to −0.723, P=0.001; I2=24.0%; Figure 3A). Significant increases in 
microglial activation were observed in caudate (SMD=1.491, 95% CI=0.586 to 2.395, 
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P=0.001; I2=0.0%) and putamen (SMD=1.355, 95% CI=0.467 to 2.242, P=0.003; 
I2=0.0%) of premanifest HDGCs (Figure 2). 
One PET study has assessed changes in striatal A1A receptor levels in premanifest 
HDGECs.52 No significant differences were found in A1A receptor levels in caudate 
(SMD=0.500, 95% CI=−0.141 to 1.142, P=0.126) and putamen (SMD=0.250, 95% 
CI=−0.386 to 0.886, P=0.441) of premanifest HDGECs compared with the group of 
HCs (Figure 2). 
 
Manifest HDGECs 
Manifest HDGECs showed significant decreases in dopamine D2 receptors in caudate 
(SMD=−5.792, 95% CI=−7.695 to −3.890, P<0.0001; I2=76.9%) and putamen 
(SMD=−5.053, 95% CI=−6.558 to −3.549, P<0.0001; I2=69.3%), D1 receptors in 
caudate (SMD=−3.648, 95% CI=−5.333 to −1.964, P<0.001; I2=58.1%) and putamen 
(SMD=−4.628, 95% CI=−8.027 to −1.230, P=0.008; I2=86.0%) and glucose 
metabolism in caudate (SMD=−3.738, 95% CI=−4.880 to −2.597, P<0.0001; 
I2=71.4%) and putamen (SMD=−1.650, 95% CI=−2.842 to −0.458, P<0.001; 
I2=86.4%; Figure 4).  
Significant decreases in striatal PDE10A (SMD=−2.445, 95% CI=−3.371 to −1.519, 
P<0.001; I2=0.0%) and CB1 receptor levels (SMD=−0.758, 95% CI=−1.472 to 
−0.044, P=0.037) were also observed in manifest HDGECs compared to the group of 
healthy controls (Figure 3B). Increases in microglial activation were observed in the 
caudate (SMD=1.748, 95% CI=0.690 to 2.806, P=0.001) and putamen (SMD=1.784, 
95% CI=0.719 to 2.848, P=0.001) of manifest HDGECs (Figure 4). 
Manifest HDGECs showed modest decreases in A1A receptor levels in caudate 
(SMD=−0.950, 95% CI=−1.741 to −0.159, P=0.019) and putamen (SMD=−0.855, 
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95% CI=−1.642 to −0.069, P=0.033; Figure 4). Significant decreases in GABA 
benzodiazepine receptors were found in the caudate (SMD=−1.612, 95% CI=−2.915 
to −0.310, P=0.015) but not in the putamen of manifest HDGECs (SMD=−0.417, 
95% CI=−1.560 to 0.727, P=0.475; Figure 4). 
Changes in presynaptic dopamine terminals were observed in two PET studies.42,43 
Decreases in DAT levels were found in caudate (SMD=−3.007, 95% CI=−4.817 to 
−1.198, P=0.001) and putamen (SMD=−3.110, 95% CI=−4.953 to −1.268, P=0.001) 
in manifest HDGECs compared to the group of HCs. VMAT2 levels were 
significantly decreased in the putamen (SMD=−0.550, 95% CI=−0.667 to −0.433, 
P<0.0001) and increased in the caudate (SMD=1.304, 95% CI=0.755 to 1.854, 
P<0.0001) of manifest HDGECs (Figure 4). 
 
Publication Bias and Sensitivity Analysis 
The Egger test was significant for [18F]FDG uptake in the caudate (P=0.022) and 
putamen (P=0.018) of manifest HDGECs indicating a risk of publication bias for this 
radioligand. Egger tests for the other outcome measures were not significant. 
Robustness of meta-analytic findings was confirmed by sequentially removing each 
study and re-analyzing the remaining data set (producing a new analysis for each 
study removed). The results remained essentially unchanged in direction and 
magnitude (results are available from the authors upon request).  
 
Supplementary analyses 
The supplementary analysis (Table 3) showed 24-25.5% and 59-60% decreases in 
caudate and putamen dopamine D2 receptor levels in premanifest and manifest 
HDGECs, respectively, and 55.7-57.4% decreases were seen in caudate and putamen 
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dopamine D1 receptor binding in manifest HDGECs. Glucose hypometabolism ranged 
between 6-11.2% and 41.4-51.3% decreases in the caudate and putamen of 
premanifest and manifest HDGECs, respectively. Premanifest HDGECs showed 
increases in microglial activation by 63.7% in caudate and 43.7% in putamen. Striatal 
PDE10A levels were decreased by 24.6% in premanifest and by 61.8% in manifest 
HDGECs compared to the HC group. 
 
DISCUSSION 
This is a comprehensive meta-analysis investigating in vivo striatal molecular changes 
in premanifest and manifest HDGECs. We found that PET molecular imaging has the 
potential to detect striatal molecular changes even at the early premanifest stage of 
HD, which are relevant to the neuropathological mechanisms underlying the 
development of the disease. Striatal molecular changes were more severe in manifest 
as compared to premanifest HDGECs.  
 
Manifest HDGECs showed significant decreases in dopamine D1, D2 receptor binding 
and glucose metabolism in caudate and putamen compared to HCs. Moreover, striatal 
PDE10A expression and CB1 receptor levels were decreased in manifest HDGECs 
whereas increased microglial activation was found in the caudate and putamen of 
manifest HDGECs. The greatest differences were observed in dopamine D1 (caudate 
SMD=−3.648; -57.7%, putamen SMD=−1.650; -55.7%) and D2 (caudate 
SMD=−5.792; -59%; putamen SMD=−5.053; -60%) receptor binding and striatal 
PDE10A expression (striatal PDE10A SMD=−2.445; -61.8%). Our findings are in 
line with the known pathological feature of HD affecting preferentially striatal 
GABAergic MSNs expressing dopamine receptors.61 Greater decreases were observed 
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in dopamine D2 receptor binding compared to dopamine D1 binding, in line with 
previous postmortem studies indicating preferential degeneration of dopamine D2 
striatopallidal external projection neurons in HD.62 Previous PET studies have shown 
that decreases in dopamine receptors are associated with longer disease duration and 
symptom severity highlighting the importance of dopaminergic signalling as a marker 
for monitoring disease progression.41,42 In premanifest HDGECs, dopamine D2 
receptor binding was also significantly decreased in caudate (SMD=−1.233; -24%) 
and putamen (SMD=−1.479; -25.5%) compared to the HCs suggesting that loss of 
dopamine D2 receptor binding can occur at the early stages of the disease. In 
premanifest HDGECs, the magnitude of striatal changes in dopamine D2 receptor 
binding was half of those observed in manifest HDGECs. In summary, the magnitude 
of the decrease in D1 binding in manifest HDGECs was similar to that of D2 binding, 
whereas only D2 binding was significantly decreased in premanifest HDGECs. This 
might presumably reflect preferential involvement of the indirect pathways in early 
stage of the disease, with less selective involvement as disease progresses, but these 
differences are unlikely to be apparent with disease progression. 
 
Striatal PDE10A expression was also severely reduced in manifest HDGECs and in 
premanifest HDGECs, though to a lesser degree compared to manifest HDGECs 
(striatal SMD=−1.663; -24.6%). Preclinical studies have suggested an important role 
of PDE10A in HD pathology.63-65 Mutant HTT decreases PDE10A mRNA expression 
levels in the striatum63,66 and inhibition of PDE10A reduces the loss of striatal and 
cortical neurons and delays the development of neurological deficits in HD animal 
models.64,65 A recent preclinical study has shown that chronic PDE10 inhibition 
starting at presymptomatic ages decreases the onset of mHTT-induced corticostriatal 
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transmission deficits and improves cortically driven indirect pathway activity in HD 
animal models.67 Our results confirm the relevance of this enzyme in HD pathology 
and suggest that PDE10A could be a potential novel biomarker of striatal MSNs 
integrity. However, due to the small sample size and number of studies, we were 
unable to directly compare loss of dopamine receptor binding and PDE10A decreases. 
A recent PET study has investigated longitudinal PDE10A changes in a small cohort 
of two premanifest and six manifest HDGECs.68 The mean annualised rate of decline 
in PDE10A was 16.6% in caudate and 6.9% in putamen of HDGECs. The rate of 
annual change of PDE10A expression was greater than the one observed in dopamine 
D2 receptors highlighting the role of this enzyme in HD pathology.
40,69,70 There is 
currently one ongoing study, PEARL-HD, evaluating the expression of PDE10A 
enzyme and dopamine D2 receptor levels using [
18F]MNI-659 and [11C]raclopride in 
premanifest and manifest HDGECs and HCs.71 In this study, [11C]raclopride and 
[18F]MNI-659 binding were significantly lower in HDGECs compared with HCs. In 
manifest HDGECs stage I dopamine D2 receptors and PDE10A availability were 
decreased by 63% and 91% in the caudate, and by 43% and 69% in the putamen 
compared to HCs. In premanifest HDGECs, the corresponding reductions were 32% 
and 53% in the caudate, 31% and 43% in the putamen. These preliminary results 
show that striatal PDE10A is already more severely reduced than striatal D2 receptors 
in HD, even at the earliest stages of the disease.71 
 
Striatal CB1 receptor levels were decreased in manifest HDGECs (striatal 
SMD=−0.758). CB1 receptors are mainly expressed on GABAergic striatal MSNs and 
are a key modulator of synaptic transmission in the brain,72 thus they may play an 
important role in the pathogenesis of HD. Further studies investigating CB1 receptor 
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levels in premanifest HDGECs and using different CB1 PET radioligand with higher 
brain uptake, faster kinetics, better time stability, and robust measurements of 
distribution volume are needed in order to further elucidate the role of these receptors 
in the pathophysiology of HD. 
 
Glucose metabolism decreases observed in this meta-analysis were smaller compared 
to loss of PDE10A and dopamine D2 receptor binding in both premanifest (caudate 
SMD=−0.758; -6%; putamen SMD=−2.462; -11.2%) and manifest (caudate 
SMD=−3.738; -51.3%; putamen SMD=−1.650; -41.4%) HDGECs compared to the 
group of HCs. These findings may suggest that glucose metabolism is a less sensitive 
marker of striatal dysfunction at the early stages of the disease. Greater reductions in 
glucose metabolism were observed in caudate than in putamen of manifest and 
premanifest HDGECs. This is consistent with histological and MRI studies showing 
that HD-related striatal atrophy follows a topographical dorsoventral and caudorostral 
gradient affecting earlier the tail and body of the caudate.73 Previous PET studies have 
found a significant association between decreased caudate glucose metabolism and 
cognitive decline in manifest HD patients.36,37 We were unable to investigate the 
potential effect of cognitive impairment modifiers on caudate glucose metabolism due 
to the lack of cognitive measures. One limitation in the interpretation of glucose 
metabolism analysis is the different methods used to quantify [18F]FDG uptake (i.e. 
glucose absolute values,  normalised to cortical or cerebellar or global metabolic 
values), that has been taken in account using subgroups analysis. Additional limitation 
is the presence of publication bias for both caudate and putamen glucose uptake; 
caution should be taken when considering the importance of altered striatal glucose 
metabolism in HDGECs. Although glucose metabolism deficits are an important 
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component of HD pathogenesis,74 [18F]FDG PET acquisition has limitations and 
heavily depends on the conditions of the study. For instance, blood glucose level may 
influence the image quality.75 High intracellular glucose and circulating insulin levels 
increase [18F]FDG uptake by the muscle and further reduce the uptake in the brain. 
Thus, [18F]FDG PET of the brain is affected both qualitatively and quantitatively by 
hyperglycemia.76 It has been recently suggested that diabetes and poor glycemic 
control decrease [18F]FDG uptake in cortical areas associated with Alzheimer’s 
disease, whereas does not influence the accumulation of amyloid-β related tracer 
[11C]PiB.77 Moreover, several psychotropic drugs including benzodiazepine can 
decrease the global brain activity and affect brain glucose metabolism.78 Lastly, 
sensorial input may also cause a bias since they can alter regional glucose 
metabolism. 
 
We found increased microglial activation in caudate and putamen of premanifest 
(caudate SMD=1.491; +43.6%; putamen SMD=1.355; +63.7%) and manifest (caudate 
SMD=1.748; putamen SMD=1.784) HDGECs. Microglial activation could contribute 
to the HD neurodegenerative processes.79 Microglia expressing mutant huntingtin 
become over-activated in response to stimulation80 and promotes the expression of 
increased pro-inflammatory cytokines contributing to tissue damage and pathogenesis 
of HD.79 Previous PET studies have reported 50% increases in striatal microglial 
activation in manifest HDGECs46,60 that correlated with loss of striatal dopamine D2 
receptor binding and motor symptom severity.60 In premanifest HDGECs, striatal 
microglial activation was also found increased and correlated with subclinical striatal 
neuronal loss of dopamine D2 receptor binding and with higher probability of 
symptomatic onset over the next 5 years.46,58,59 However, our results should be 
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interpreted cautiously due to the small sample size, limited number of studies 
included and radioligand limitation. [11C]PK11195 shows high level of non-specific 
binding and a poor signal-to-noise ratio,81 which complicates its quantification; 
moreover, test–retest data in control subjects showed only moderate intra-individual 
reproducibility82  as compared to [11C]raclopride.83 
 
Other striatal molecular changes were observed in this meta-analysis. Striatal A1A 
receptor levels were found decreased in manifest but not in premanifest HDGECs. 
Decreases in GABA benzodiazepine receptors were observed only in the caudate of 
manifest HDGECs. Striatal DAT binding was decreased in manifest HDGECs 
whereas decreases in VMAT2 levels was found only in the putamen of manifest 
HDGECs. The increased VMAT2 binding observed in the caudate of manifest 
HDGECs might reflect loss of volume with increased density of nerve terminals 
projecting to the caudate, however the small sample size and difficulty in correcting 
for atrophy make this assumption speculative. Only one study reported decreases in 
both caudate and putamen DAT binding in manifest HDGECs. This study has several 
limitations including the small sample size (only five HDGECs), the lack of 
correction for striatal atrophy and the PET analysis method employed. Striatal [11C]β-
CIT uptake kinetics is not irreversible and do not fully satisfy the constraints of 
multiple-time graphical analysis (MTGA) model assumptions. Additionally, 
neuroleptics drugs and tetrabenazine, commonly used in HD, interfere with the 
release of dopamine at the presynaptic terminal. Both studies did not report whether 
HDGECs were on dopamine modulating drugs, which could have influenced VMAT2 
and DAT availability. Therefore, these results should be interpreted cautiously and 
further studies in larger cohort of HDGECs using appropriate partial volume 
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correction methods are needed in order to further elucidate the integrity of presynaptic 
dopaminergic terminals in HD.  
 
The main limitation of our meta-analysis is that it was carried out on a few studies 
and this limited meta-regression analysis. Additional limitations include the small 
sample size and a low quality of some studies that represent a potential risk of bias. 
Several PET studies included in this meta-analysis did not employ partial volume 
correction methods,34-37,38-42,45,47,50,51,54 thus striatal neuronal loss occurring in HD 
might have influenced the outcome measurement accuracy in relation to the actual 
target change.  
 
CONCLUSIONS 
It is challenging to perform PET imaging studies in HDGECs due to low prevalence 
and progressive course of the disease leading to severe cognitive and motor deficits. 
This systemic review and meta-analysis is nevertheless the best evidence to date 
demonstrating significant striatal molecular changes in manifest and to a lesser degree 
in premanifest HDGECs. Despite 20 years of PET research in HDGECs, conclusions 
are limited and further larger studies are needed for understanding the biological 
signature of the different PET biomarkers across the stages of HDGECs, which could 
be used to monitor disease progression and response to medications in therapeutic 
trials. A longitudinal PET study that attempts to address multiple PET biomarkers 
across the different stage of HD will be able to characterize potential longitudinal 
progression and pharmacodynamic biomarkers that could be used as markers of 
treatment response in therapeutic development for HDGECs. 
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FIGURE LEGENDS 
Fig. 1 Search strategy for identifying PET studies in manifest and premanifest 
HDGECs. 
 
Fig. 2 Pooled analysis (SMD) for in vivo PET molecular changes in the caudate and 
putamen of premanifest HDGECs. 
 
Fig. 3 Pooled analysis (SMD) for in vivo striatal PET molecular changes in 
premanifest (A) and manifest (B) HDGECs. 
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Fig. 4 Pooled analysis (SMD) for in vivo PET molecular changes in the caudate and 
putamen of manifest HDGECs. 
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Table 1 PET studies included in the meta-analysis for the group of premanifest Huntington’s disease gene expansion carriers 
Study and Group Radioligand N Age (years) Prob to onset CAGr 
Total Male (%) Mean Range p5  
years1 
90% 
p to 
onset2 
Mean Range 
D2 receptor 
Antonini et al., 1996 [11C]raclopride         
HC  14 - 30 21-49     
premanifest HD  10 50 30 21-41 0.12 26.7 43.9 40-47 
Politis et al., 2008 [11C]raclopride         
HC  9 89.5 41.2 5.5*     
premanifest HD  10 50 41.9 32-61 0.33 16.9 43.4 39-48 
van Oostrom et al., 2009 [11C]raclopride         
 33 
HC  11 54 48.4 30-65     
premanifest HD  18 44 39.9 29-56 0.21 19.5 43 39-47 
Tang et al., 2013 [11C]raclopride         
HC  12 42.5 50.1 15.6*     
premanifest HD  12 46.8 48.3 11.0* 0.33 10.3 41.6 1.7* 
Microglial activation 
Politis et al., 2008 [11C]PK11195         
HC  10 89.5 56.7 11.7*     
premanifest HD  10 50 41.9 32-61 0.33 16.9 43.4 39-48 
Politis et al., 2015 [11C]PK11195         
HC  12 58.3 39.4 28-65     
premanifest HD  12 41.7 41.1 29-59 0.32 17.9 43.7 40-48 
Glucose metabolism 
Antonini et al., 1996 [18F]FDG         
 34 
HC  20 - 34 22-44     
premanifest HD  13 50 30 21-41 0.17 23.7 43.9 40-47 
Feigin et al., 2007 [18F]FDG         
HC  12 42.5 50.1 15.6*     
premanifest HD  12 46.8 48.3 11.0* 0.33 10.3 41.6 1.7* 
Ciarmiello et al., 2012 [18F]FDG         
HC  21 57.1 68.1 48-91     
premanifest HD  43 55.8 37.3 19-59 0.25 18 43.8 39-54 
Herben-Dekker et al., 
2014 
[18F]FDG         
HC  11 33 42.5 26-54     
premanifest HD  22 36 38.7 31-56 0.19 22.4 42.6 39-47 
Phosphodiesterase 10 A 
Russell et al., 2014 [18F]MNI-659         
 35 
HC  9 55 46.1 29-71     
premanifest HD  3 0 32.4 32-34 0.18 22.3 44.3 42-47 
Niccolini et al., 2015 [11C]IMA107         
HC  12 66.7 40 28-50     
premanifest HD  12 58.3 41.1 32-52 0.16 25 41.8 40-44 
Adenosine A1 receptor 
Matush et al., 2014 [18F]CPFPX         
HC  36 63.9 49.6 16*     
premanifest HD  13 23.1 39.1 7* 0.19 13 42.8 1.4* 
1p5 years= 5-year probability to symptoms onset according to the Langbehn formula;10 290% p to onset = predicted years to 
Huntington’s disease symptoms onset (90% probability) calculated on the basis of the variant of the survival analysis formula 
described by Langbehn;5 HC=healthy controls; HD=Huntington’s disease; *Standard deviation. 
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Table 2 PET studies included in the meta-analysis for the group of manifest Huntington’s disease gene expansion carriers 
Study and Group PET ligand N Age (years) Disease 
duration 
(years) 
CAGr 
Total Male (%) Mean Range Mean Range 
D1 receptor 
Turjanski et al., 1995 [11C]SCH23390        
HC  6 - 51 31-78    
Manifest HD  10 50 48 29-72 3   
Backman et al., 1997 [11C]SCH23390        
HC  5 60 48 7.8*    
Manifest HD  5 60 49.4 7.6* 5.6   
Furtado et al., 2005 [11C]SCH23390        
HC  4 - - -    
Manifest HD  7 - - - -   
 37 
D2 receptor 
Turjanski et al., 1995 [11C]raclopride        
HC  9 - 50 24-74    
Manifest HD  10 50 48 29-72 3   
Antonini et al., 1996 [11C]raclopride        
HC  14 - 30 21-49    
Manifest HD  8 75 44 34-52 2.2 44 42-48 
Ginovart et al., 1997 [11C]raclopride        
HC  5 - -     
Manifest HD  5 60 49.4 37-56 - - - 
Backman et al., 1997 [11C]raclopride        
HC  5 60 48 7.8*    
Manifest HD  5 60 49.4 7.6* 5.6 - - 
Politis et al., 2008 [11C]raclopride        
 38 
HC  9 100 41.2 5.5*    
Manifest HD  9 44.4 46.8 39-54 7.25 41.5 36-51 
Furtado et al., 2005 [11C]raclopride        
HC  10 - - -    
Manifest HD  7 - - - - - - 
Microglial activation 
Politis et al., 2008 [11C]PK11195        
HC  10 89.5 56.7 11.7*    
Manifest HD  9 44.4 46.8 39-54 7.25 41.5 36-51 
Glucose metabolism 
Hayden et al., 1986 [18F]FDG        
HC  7 - 49.3  23-66    
Manifest HD  10 50 45.3  33-61 2.6 - - 
Young et al., 1986 [18F]FDG        
 39 
HC  10  37.5 25-65    
Manifest HD  10  40.5 25-65 - - - 
Berent et al., 1988 [18F]FDG        
HC  14 - 37.5 25-65 -   
Manifest HD  15 - 40.5 25-60 - - - 
Kuwert et al., 1990 [18F]FDG        
HC  20 71.4 41.1 25-65    
Manifest HD  23 52.2 42.7 25-65 - - - 
Antonini et al., 1996 [18F]FDG        
HC  20  34 22-44    
Manifest HD  8 75 44 34-52 - 44 42-48 
Furtado et al., 2005 [18F]FDG        
HC  10 - - -    
Manifest HD  7 - - - - - - 
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Shin et al., 2013 [18F]FDG        
HC  11 45.5 48.6     
Manifest HD  13 38.5 46.4 36-76 6.5 44.7 36-55 
Phosphodiesterase 10 A 
Ahmad et al., 2014 [18F]JNJ422591
52 
       
HC  11 63.6 56.8 47-78    
Manifest HD  5 80 50.8 42-70 3.2 44 43-46 
Russell et al., 2014 [18F]MNI-659        
HC  9 55 46.1 29-71    
Manifest HD  8 25 51.8 20-67 - 45.3 40-68 
GABA benzodiazepine receptor 
Holthoff et al., 1993 [11C]FMZ        
HC  6 - 50 13*    
 41 
Manifest HD  6 50 53 9* 4.5 - - 
Dopamine transporter 
Ginovart et al., 1997 [11C]β-CIT        
HC  5 - -     
Manifest HD  5 60 49.4 37-56 - - - 
Vesicular monoamine transporter type-2  
Bohnen et al., 2000 [11C]DTBZ        
HC  64 50 50 23-70     
Manifest HD  19 68.4 48 16* - - - 
Cannabinoid type 1 receptor  
van Laere et al., 2010 [18F]MK9470        
HC  14 42.8 54.3 31-68    
Manifest HD  20 40 53.3 32-83  6 43.6 39-50 
Adenosine A1 receptor 
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Matush et al., 2014 [18F]CPFPX        
HC  36 63.9 49.6 16*    
Manifest HD  8 62.5 46.6 5* 2.3 43.3 1.5* 
HC=healthy controls; HD=Huntington’s disease; *Standard deviation 
 
 
 
Table 3. Percentage change for the outcome measures between premanifest and manifest HDGECs and HCs.  
Premanifest HDGECs 
 ROIs 
Groups Mean S.D. Min 
25%th 
quartile 
Median 
75%th 
quartile 
Max 
D2 Caudate pHDGECs 1.78 0.56 1.25 1.27 1.74 2.31 2.37 
HCs 2.33 0.67 1.49 1.64 2.47 2.88 2.89 
Differences -0.24 -0.37 -0.73 -0.57 -0.52 -0.56 -0.11 
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(% changes) (-23.8%) 
Putamen pHDGECs 2.06 0.46 1.37 1.59 2.27 2.32 2.32 
HCs 2.76 0.51 2.07 2.24 2.86 3.19 3.26 
Differences 
(% changes) 
-0.70 
(-25.5%) 
-0.05 -0.70 -0.65 -0.59 -0.87 -0.94 
FDG Caudate pHDGECs 1.04 0.21 0.80 0.80 1.12 1.19 1.19 
HCs 1.10 0.20 0.88 0.88 1.18 1.25 1.25 
Differences 
(% changes) 
-0.08 
(-6.0%) 
-0.08 -0.06 -0.06 -0.06 -0.07 0.01 
Putamen pHDGECs 1.00 0.23 0.74 0.74 1.10 1.17 1.17 
HCs 1.13 0.18 0.93 0.93 1.20 1.26 1.26 
Differences 
(% changes)  
-0.13 
(-11.2%) 
0.05 -0.19 -0.19 -0.10 -0.09 -0.09 
PK Caudate pHDGECs 0.19 0.06 0.15 0.15 0.19 0.23 0.23 
 44 
HCs 0.07 0.09 0.01 0.01 0.07 0.13 0.13 
Differences 
(% changes) 
+0.12 
(+63.7%) 
0.14 0.12 0.10 0.10 0.12 -0.03 
Putamen pHDGECs 0.28 0.06 0.23 0.23 0.28 0.32 0.32 
HCs 0.16 0.04 0.13 0.13 0.16 0.18 0.18 
Differences 
(% changes)  
+0.12 
(+43.6%) 
0.03 0.10 0.10 0.12 0.14 0.14 
PDE10A Striatum pHDGECs 1.26 1.26 1.74 2.21 2.21 1.74 0.67 
HCs 1.81 1.81 2.30 2.79 2.79 2.30 0.69 
Differences 
(% changes) 
-0.55 
(-24.6%) 
-0.55 -0.57 -0.58 -0.58 -0.57 -0.02 
Manifest HDGECs 
 ROIs 
Groups Mean SD Min 
25%th 
quartile 
Median 
75%th 
quartile 
Max 
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D1 Caudate HDGECs 0.55 0.10 0.47 0.47 0.52 0.67 0.67 
HCs 1.3 0.15 1.13 1.13 1.38 1.39 1.39 
Differences 
(% changes) 
-0.75 
(-57.4%) 
-0.04 -0.66 -0.66 -0.86 -0.72 -0.72 
Putamen HDGECs 0.59 0.23 0.39 0.39 0.53 0.84 0.84 
HCs 1.32 0.04 1.28 1.28 1.34 1.35 1.35 
Differences 
(% changes) 
-0.74 
 (-55.7%) 
0.19 -0.89 -0.89 -0.81 -0.51 -0.51 
D2 Caudate HDGECs 0.99 0.43 0.22 0.69 1.10 1.28 1.45 
HCs 2.41 0.37 2.08 2.08 2.29 2.86 2.89 
Differences 
(% changes) 
-1.42 
(-59.0%) 
0.06 -1.85 -1.39 -1.19 -1.58 -1.44 
Putamen HDGECs 1.03 0.56 0.15 0.58 1.15 1.49 1.53 
HCs 2.58 0.37 2.25 2.32 2.46 2.89 3.26 
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Differences 
(% changes) 
-1.55 
(-60.0%) 
0.18 -2.07 -1.73 -1.30 -1.38 -1.73 
FDG Caudate HDGECs 2.31 1.65 0.47 0.66 2.43 3.35 5 
HCs 13.16 20.82 0.91 1.11 6.87 19.73 55.2 
Differences 
(% changes) 
-1.8 
(-51.3%) 
-19.17 -0.44 -0.448 -4.445 -16.38 -50.2 
Putamen HDGECs 3.09 2.13 0.59 0.81 3.25 4.89 6.1 
HCs 5.28 3.25 1.05 1.21 6.73 7.82 8.2 
Differences 
(% changes) 
-2.19 
(-41.4%) 
-1.13 -0.46 -0.40 -3.48 -2.93 -2.1 
PDE10A Striatum HDGECs 1.33 0.25 1.15 1.15 1.33 1.50 1.50 
HCs 3.47 0.96 2.79 2.79 3.47 4.15 4.15 
Differences 
(% changes) 
-1.64 
(-61.8%) 
-1.64 -2.15 -2.65 -2.65 -2.15 -0.71 
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Mean, standard deviation, minimum, 25th, 50th and 75th quartile and maximum are presented for each group separately and all 
studies together. The % change is shown for premanifest and manifest HDGECs and HC groups separately as well as the 
difference in % change between HDGECs and HCs groups. 
 
